Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4666 to 4680 of 7684 results

  1. Further research is recommended on:• the impact of LiverMultiScan test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of LiverMultiScan compared with biopsy, or the prognostic ability of LiverMultiScan to predict clinical outcomes (see section 3.19 ).

    Recommendation ID DG50/01 Question Further research is recommended on:• the impact of LiverMultiScan test results on decisions about care

    Research recommendation
    Published
    3 February 2023

  2. Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF ratio), with standard clinical assessment, in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation, who have had a negative PlGF-based test result (Triage PlGF test result of 100 picograms/ml or more; Elecsys immunoassay sFlt 1/PlGF ratio of less than 38) that was used to rule-out pre-eclampsia. This should include:- exploration of the different scenarios in which repeat testing may be indicated- the appropriate intervals between PlGF-based tests- the diagnostic accuracy of PlGF-based testing in women with suspected pre-eclampsia who have previously had 1 or more negative PlGF-based test results.

    Recommendation ID DG23/1 Question Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys

    Research recommendation
    Published
    22 June 2016

  3. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    Recommendation ID DG50/02 Question Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results

    Research recommendation
    Published
    3 February 2023

  4. Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium] acid) test results affect clinical decision making.

    Recommendation ID DG44/01 Question Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium]

    Research recommendation
    Published
    16 December 2021

  5. Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems on the rate at which biopsies can be done, capacity resources and waiting times for this procedure.

    Recommendation ID DG53/2 Question Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems

    Research recommendation
    Published
    11 July 2023

  6. Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the accuracy of the tests included in this assessment in the following subgroups:- people who are premenopausal- people who are postmenopausal- people with suspected early stage ovarian cancer, that is, disease apparently confined to the pelvis.Future studies should be done in populations that are representative of people with suspected ovarian cancer who are assessed in NHS secondary care.

    Recommendation ID DG31/1 Question Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the

    Research recommendation
    Published
    18 October 2018

  7. Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and its effect on healthcare resource use. myCOPD has potential for clinical benefits, but more evidence is needed to reduce uncertainties. The committee considered that comparative evidence is needed to show the clinical benefits of using myCOPD in 2 populations: people using it to self-manage COPD people referred to pulmonary rehabilitation For self-management, a randomised controlled trial is preferred to show the clinical benefits of myCOPD. This could be powered based on the encouraging results in the RESCUE study. However, a high-quality comparative observational study designed to minimise bias in the results may provide acceptable evidence. Outcomes such as rates of exacerbations, hospital readmissions and unscheduled care appointments should be considered alongside patient-reported outcomes such as health-related quality of life. For pulmonary rehabilitation, further evidence is needed to show the clinical benefits of myCOPD. This could be a randomised controlled trial which is powered based on the encouraging results in the TROOPER study or a well-designed comparative observational study. Key outcomes will be the CAT score and 6-minute walk test, ideally supported by additional longer-term outcomes such as rates of exacerbations and hospital admissions. Real-world data could be used to inform the uptake rates in the economic modelling. It should also include qualitative data on patient experience using myCOPD such as patient preferences and adherence.

    Recommendation ID MTG68/01 Question Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and

    Research recommendation
    Published
    8 April 2022

  8. A randomised controlled trial is recommended to compare DyeVert Systems  with standard care. The aim of this research would be to address uncertainties  about whether using DyeVert Systems reduces AKI incidence and rate of renal  replacement therapy after using contrast media. This must include people with  stage 4 chronic kidney disease (with an estimated glomerular filtration rate  [eGFR] under 30 ml/min/1.73 m 2 ), who are at risk of AKI and need elective  coronary or peripheral angiography.

    Recommendation ID MTG60/01 Question A randomised controlled trial is recommended to compare DyeVert Systems with standard care. The aim

    Research recommendation
    Published
    5 November 2021

  9. Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic monitoring of TNF‑alpha inhibitors in people with rheumatoid arthritis.

    Recommendation ID DG36/1 Question Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic

    Research recommendation
    Published
    25 October 2019

  10. Further research and publication of observational data would be useful. Publications should describe details of patient selection, particularly in relation to previous treatments. They should also describe clinical outcomes (including all complications) and patient experience in the longer term. NICE may review the procedure on publication of further evidence.

    Recommendation ID IPG439/1 Question Further research and publication of observational data would be useful. Publications should describe

    Research recommendation
    Published
    9 June 2015

  11. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    Recommendation ID TA214/1 Question Further research designed to investigate differences in health-related quality of life and the clinical

    Research recommendation
    Published
    9 June 2015

  12. Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia should report details of patient selection (including prostate size and the amount of median lobe enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and outcome measures of sexual function using established methods.

    Recommendation ID IPG641/1 Question Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of

    Research recommendation
    Published
    18 February 2019

  13. Further research including the use of observational data from registries should provide information on patient selection, safety outcomes, quality of life, long-termoutcomes and the position of the procedure in the treatment pathway. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG598/1 Question Further research including the use of observational data from registries should provide information

    Research recommendation
    Published
    18 October 2018

  14. Further research in low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing should include details of patient selection, fracture site, and risk factors and comorbidities that delay fracture healing.

    Recommendation ID IPG622/1 Question Further research in low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk

    Research recommendation
    Published
    11 December 2018

  15. Further research into arthroscopic radiofrequency chondroplasty of the knee should clearly document patient selection and the types of chondral defects being treated. More evidence on long-term outcomes would be useful.

    Recommendation ID IPG493/1 Question Further research into arthroscopic radiofrequency chondroplasty of the knee should clearly document

    Research recommendation
    Published
    9 June 2015